Log in

NASDAQ:OVID - Ovid Therapeutics Stock Price, Forecast & News

$2.89
+0.04 (+1.40 %)
(As of 03/29/2020 02:24 PM ET)
Today's Range
$2.72
Now: $2.89
$3.07
50-Day Range
$2.03
MA: $3.16
$4.35
52-Week Range
$1.53
Now: $2.89
$5.24
Volume735,342 shs
Average Volume713,707 shs
Market Capitalization$158.11 million
P/E RatioN/A
Dividend YieldN/A
Beta2.54
Ovid Therapeutics Inc., a biopharmaceutical company, develops impactful medicines for patients and families with neurological disorders in the United States. The company is developing OV101, a drug candidate, which has completed Phase II clinical trial for adults with angelman syndrome; and Phase I clinical trial for adolescents with angelman syndrome or fragile X syndrome. It is also developing OV935, a drug candidate, which has completed Phase 1b/2a trial for rare epileptic encephalopathies. The company has collaboration agreement with Takeda Pharmaceutical Company Limited; and a license agreement with H. Lundbeck A/S. Ovid Therapeutics Inc. was founded in 2014 and is headquartered in New York, New York.
Read More
Ovid Therapeutics logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:OVID
CUSIPN/A
Phone646-661-7661

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$1.46 per share

Profitability

Net Income$-60,460,000.00

Miscellaneous

Employees55
Market Cap$158.11 million
Next Earnings Date5/5/2020 (Estimated)
OptionableNot Optionable

Receive OVID News and Ratings via Email

Sign-up to receive the latest news and ratings for OVID and its competitors with MarketBeat's FREE daily newsletter.


Ovid Therapeutics (NASDAQ:OVID) Frequently Asked Questions

How has Ovid Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Ovid Therapeutics' stock was trading at $2.68 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, OVID stock has increased by 7.8% and is now trading at $2.89. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Ovid Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Ovid Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Ovid Therapeutics.

When is Ovid Therapeutics' next earnings date?

Ovid Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Ovid Therapeutics.

How were Ovid Therapeutics' earnings last quarter?

Ovid Therapeutics Inc (NASDAQ:OVID) announced its quarterly earnings data on Wednesday, March, 11th. The company reported ($0.35) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.41) by $0.06. View Ovid Therapeutics' earnings history.

What price target have analysts set for OVID?

6 analysts have issued 12-month price targets for Ovid Therapeutics' stock. Their forecasts range from $10.00 to $20.00. On average, they anticipate Ovid Therapeutics' stock price to reach $14.00 in the next twelve months. This suggests a possible upside of 384.4% from the stock's current price. View analysts' price targets for Ovid Therapeutics.

Has Ovid Therapeutics been receiving favorable news coverage?

Media stories about OVID stock have trended extremely negative on Sunday, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Ovid Therapeutics earned a daily sentiment score of -4.0 on InfoTrie's scale. They also assigned news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the next few days. View the latest news aboutOvid Therapeutics.

Are investors shorting Ovid Therapeutics?

Ovid Therapeutics saw a increase in short interest in the month of March. As of March 13th, there was short interest totaling 2,216,300 shares, an increase of 21.8% from the February 27th total of 1,820,000 shares. Based on an average daily trading volume, of 629,400 shares, the short-interest ratio is presently 3.5 days. Currently, 9.8% of the company's stock are short sold. View Ovid Therapeutics' Current Options Chain.

Who are some of Ovid Therapeutics' key competitors?

What other stocks do shareholders of Ovid Therapeutics own?

Who are Ovid Therapeutics' key executives?

Ovid Therapeutics' management team includes the following people:
  • Dr. Jeremy Max Levin, Chairman & CEO (Age 66)
  • Dr. Matthew J. During, Founder, Chairman of Scientific Advisory Board & Director (Age 62)
  • Ms. Lora Pike, Sr. Director of Investor Relations & PR
  • Ms. Ana C. Ward Esq., M.S., M.B.A., Sr. VP, Gen. Counsel & Sec. (Age 50)
  • Mr. Thomas Michael Perone, Sr. VP, Gen. Counsel & Sec.

When did Ovid Therapeutics IPO?

(OVID) raised $80 million in an IPO on Friday, May 5th 2017. The company issued 5,000,000 shares at a price of $15.00-$17.00 per share. Citigroup and Cowen and Company acted as the underwriters for the IPO and William Blair and JMP Securities were co-managers.

What is Ovid Therapeutics' stock symbol?

Ovid Therapeutics trades on the NASDAQ under the ticker symbol "OVID."

Who are Ovid Therapeutics' major shareholders?

Ovid Therapeutics' stock is owned by a variety of retail and institutional investors. Top institutional investors include FMR LLC (4.36%), Renaissance Technologies LLC (2.27%), AXA (1.81%), BVF Inc. IL (1.54%), Citigroup Inc. (1.05%) and Ikarian Capital LLC (0.73%). Company insiders that own Ovid Therapeutics stock include Douglas E Williams, Jeremy M Levin, Karen Bernstein and Pharmaceutical Co Ltd Takeda. View institutional ownership trends for Ovid Therapeutics.

Which major investors are selling Ovid Therapeutics stock?

OVID stock was sold by a variety of institutional investors in the last quarter, including BVF Inc. IL, and Acadian Asset Management LLC. View insider buying and selling activity for Ovid Therapeutics.

Which major investors are buying Ovid Therapeutics stock?

OVID stock was acquired by a variety of institutional investors in the last quarter, including FMR LLC, AXA, Citigroup Inc., Renaissance Technologies LLC, Ikarian Capital LLC, Credit Suisse AG, Blair William & Co. IL, and Platinum Investment Management Ltd.. Company insiders that have bought Ovid Therapeutics stock in the last two years include Douglas E Williams, Jeremy M Levin, Karen Bernstein, and Pharmaceutical Co Ltd Takeda. View insider buying and selling activity for Ovid Therapeutics.

How do I buy shares of Ovid Therapeutics?

Shares of OVID can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Ovid Therapeutics' stock price today?

One share of OVID stock can currently be purchased for approximately $2.89.

How big of a company is Ovid Therapeutics?

Ovid Therapeutics has a market capitalization of $158.11 million. The company earns $-60,460,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. Ovid Therapeutics employs 55 workers across the globe. View additional information about Ovid Therapeutics.

What is Ovid Therapeutics' official website?

The official website for Ovid Therapeutics is http://www.ovidrx.com/.

How can I contact Ovid Therapeutics?

Ovid Therapeutics' mailing address is 1460 Broadway Suite 15044, New York NY, 10036. The company can be reached via phone at 646-661-7661 or via email at [email protected]


MarketBeat Community Rating for Ovid Therapeutics (NASDAQ OVID)

Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  299 (Vote Outperform)
Underperform Votes:  237 (Vote Underperform)
Total Votes:  536
MarketBeat's community ratings are surveys of what our community members think about Ovid Therapeutics and other stocks. Vote "Outperform" if you believe OVID will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OVID will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 3/29/2020 by MarketBeat.com Staff

Featured Article: What is a SEC Filing?

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel